search
Back to results

Hypertension Prevention Trial (HPT) Feasibility Study

Primary Purpose

Cardiovascular Diseases, Heart Diseases, Hypertension

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
diet, sodium-restricted
diet, reducing
potassium
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiovascular Diseases

Eligibility Criteria

25 Years - 49 Years (Adult)All SexesDoes not accept healthy volunteers

Men and women, ages 25 to 49. Diastolic blood pressure between 78 and 89 mm Hg. Free of major disease. Not on a special diet or antihypertensive medication at entry. Some mild to moderately obese subjects.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    October 27, 1999
    Last Updated
    November 25, 2013
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00000501
    Brief Title
    Hypertension Prevention Trial (HPT) Feasibility Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    September 1981 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    August 1986 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    5. Study Description

    Brief Summary
    To test the feasibility and the efficacy of nutritional interventions in the primary prevention of hypertension in individuals predisposed to the development of hypertension; specifically, to test the hypothesis that reduction of weight and/or decreased sodium intake in obese individuals, or decreased sodium intake with or without increased potassium intake (in men and women, regardless of weight) would prevent the elevation of blood pressure and the incidence of hypertension.
    Detailed Description
    BACKGROUND: The nature of essential hypertension as a mass public health problem throughout the United States, and internationally as well, is recognized generally. Prevalence estimates exceed l5 percent in most adult populations. Further, the results of the Hypertension Detection and Follow-up Program (HDFP) demonstrated the efficacy of antihypertensive therapy even at the 90-l05 mmHg level, which comprises 72 percent of the total hypertensive population. The Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure recommended treatment of mild hypertension by pharmacologic or non-pharmacologic therapy to the lowest diastolic pressure consistent with safety and tolerance. The recommendation was consonant with the goal blood pressure guidelines for those with baseline pressures from 90-99 mmHg. Hence, there appeared to be a growing consensus that reduction of blood pressure to levels as low as 80 mmHg might be desirable for optimal cardiovascular health. The Joint National Committee further recommended that, in young patients with uncomplicated mild hypertension, the benefits from pharmacologic therapy must be weighed against the cost, inconvenience, and possible side effects. There was, therefore, a growing concern over the need for pharmacologic management of hypertension and the public health implications of such a course of action. These recommendations toward intervention in mild hypertension set a firm basis for the primary prevention of hypertension. The association between obesity and elevated blood pressure was widely recognized. Among hypertensive individuals, numerous studies had shown that short term weight reduction by caloric restriction resulted in a reduction of blood pressure. Results of several reports of long-term follow-up of weight reduction efforts indicated that long-term control of weight at levels compatible with the objectives of the HPT was feasible. A number of investigators had achieved these levels one or more years after treatment despite minimal intervention efforts during the follow-up period. There was strong circumstantial evidence relating sodium intake to hypertension. Most impressive evidence came from the study of the 'low-salt tribes', subsisting on a very low sodium intake. They failed to develop hypertension, or even gradual rise of blood pressure with age. Many studies published on the effect of lowering sodium intake on blood pressure of hypertensive patients had been positive. In one investigation, blood pressure fell approximately 9 (systolic)/6 (diastolic) mmHg when sodium intake was reduced from approximately l80 to l00 mEq/day. Reduction of sodium intake to a level of 70-l00 mEq/day appeared within the capability of most people and maintenance up to a period of two years had been indicated with minimal follow-up procedures. The role of potassium intake in the development and treatment of hypertension was less clear. As noted above, primitive cultures studied epidemiologically had low sodium intakes associated with low prevalence and incidence of hypertension but these cultures also consumed higher levels of potassium. It has been suggested that the ratio of sodium to potassium may be the most important determinant of blood pressure. Hygienic intervention to increase potassium intake in free-living populations was the least studied of the procedures used in the HPT. Potassium intakes > l00 mEq could be achieved without the use of dietary supplements if individuals consumed large quantities of fruits and vegetables. This natural intake could also be increased by use of potassium-based baking powder and seasonings. The study was carried out by four clinical and two resource centers (a Coordinating Center and a Nutrition and Educational Resource Center). It was to be Phase l of a long-term intervention trial to determine whether development of hypertension could be prevented in a population at special risk. The initial phase of the study was directed towards testing the feasibility of the intervention, alternative modes of recruitment, quantification of sodium and potassium intake, trends in blood pressure, and the pre-testing of various study procedures. Each of the four clinical centers recruited 200 or more eligible 25 to 49 year old individuals (total 841), either identified through any of a number of multiple community sources, or through an index of hypertensive cases. The clinical investigators aided by statistical and data processing support from the Data Coordinating Center and intervention support through a special Nutrition and Education Resources Center, formed the collaborative group to test the working hypothesis. The study protocol was completed in the fall of 1982. Recruitment ended September 30, 1983. The three-year follow-up period ended August 1986. Analysis of the data ended in December 1988. DESIGN NARRATIVE: A randomized, non-blind design with three treatment groups (non-obese) or five groups (obese), including a no-treatment group in each weight stratum. Intervention methods were dietary only, and included sodium restriction, sodium restriction plus potassium supplementation (obese and non-obese), weight reduction, and weight reduction plus sodium restriction (obese only). This was a pilot study with measures of feasibility including recruitment success, dietary adherence, and blood pressure differences among the treatment groups.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardiovascular Diseases, Heart Diseases, Hypertension, Obesity, Vascular Diseases

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 2
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Behavioral
    Intervention Name(s)
    diet, sodium-restricted
    Intervention Type
    Behavioral
    Intervention Name(s)
    diet, reducing
    Intervention Type
    Drug
    Intervention Name(s)
    potassium

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    25 Years
    Maximum Age & Unit of Time
    49 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Men and women, ages 25 to 49. Diastolic blood pressure between 78 and 89 mm Hg. Free of major disease. Not on a special diet or antihypertensive medication at entry. Some mild to moderately obese subjects.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nemat Borhani
    Organizational Affiliation
    University of California, Davis
    First Name & Middle Initial & Last Name & Degree
    Robert Jeffery
    Organizational Affiliation
    University of Minnesota
    First Name & Middle Initial & Last Name & Degree
    Herbert Langford
    Organizational Affiliation
    University of Mississippi Medical Center
    First Name & Middle Initial & Last Name & Degree
    Albert Oberman
    Organizational Affiliation
    University of Alabama at Birmingham
    First Name & Middle Initial & Last Name & Degree
    Ronald Prineas
    Organizational Affiliation
    University of Minnesota

    12. IPD Sharing Statement

    Citations:
    Citation
    Hypertension Prevention Trial Research Group: Hypertension Prevention Trial--First Year Dietary Changes. In Strasser T, Ganten D, (Eds.). Mild Hypertension: From Drug Trials to Practice, New York, Raven Press, 1987.
    Results Reference
    background
    PubMed Identifier
    2680271
    Citation
    Meinert CL, Borhani NO, Langford HG. Design, methods, and rationale in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989 Sep;10(3 Suppl):1S-29S. doi: 10.1016/0197-2456(89)90040-8.
    Results Reference
    background
    PubMed Identifier
    2680272
    Citation
    Borhani NO, Tonascia J, Schlundt DG, Prineas RJ, Jefferys JL. Recruitment in the Hypertension Prevention trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989 Sep;10(3 Suppl):30S-39S. doi: 10.1016/0197-2456(89)90041-x.
    Results Reference
    background
    PubMed Identifier
    2680273
    Citation
    Brown KM, Oberman A, Van Natta ML, Forster JL. Baseline characteristics in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989 Sep;10(3 Suppl):40S-64S. doi: 10.1016/0197-2456(89)90042-1.
    Results Reference
    background
    PubMed Identifier
    2680274
    Citation
    Jeffery RW, Tonascia S, Bjornson-Benson W, Schlundt DG, Sugars C. Treatment in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989 Sep;10(3 Suppl):65S-83S. doi: 10.1016/0197-2456(89)90043-3.
    Results Reference
    background
    PubMed Identifier
    2680275
    Citation
    Prud'homme GJ, Canner PL, Cutler JA. Quality assurance and monitoring in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989 Sep;10(3 Suppl):84S-94S. doi: 10.1016/0197-2456(89)90044-5.
    Results Reference
    background
    Citation
    Tonascia J, Donithan M, Tonascia S, et al for the Hypertension Prevention Trial Research Group: Hypertension Prevention Trial: Estimation of 24-hour Sodium and Potassium Excretion from Overnight Urine Collections. Baltimore, Maryland, Department of Biostatistics, Johns Hopkins University, Technical Report 703, 1989.
    Results Reference
    background
    PubMed Identifier
    2606089
    Citation
    Shah M, Jeffery RW, Hannan PJ, Onstad L. Relationship between socio-demographic and behaviour variables, and body mass index in a population with high-normal blood pressure: Hypertension Prevention Trial. Eur J Clin Nutr. 1989 Sep;43(9):583-96.
    Results Reference
    background
    PubMed Identifier
    2404477
    Citation
    The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Hypertension Prevention Trial Research Group. Arch Intern Med. 1990 Jan;150(1):153-62.
    Results Reference
    background
    PubMed Identifier
    2187695
    Citation
    Jeffery RW, French SA, Schmid TL. Attributions for dietary failures: problems reported by participants in the Hypertension Prevention Trial. Health Psychol. 1990;9(3):315-29. doi: 10.1037//0278-6133.9.3.315.
    Results Reference
    background
    PubMed Identifier
    2407098
    Citation
    Forster JL, Jeffery RW, VanNatta M, Pirie P. Hypertension prevention trial: do 24-h food records capture usual eating behavior in a dietary change study? Am J Clin Nutr. 1990 Feb;51(2):253-7. doi: 10.1093/ajcn/51.2.253.
    Results Reference
    background
    PubMed Identifier
    2404050
    Citation
    Shah M, Jeffery RW, Laing B, Savre SG, Van Natta M, Strickland D. Hypertension Prevention Trial (HPT): food pattern changes resulting from intervention on sodium, potassium, and energy intake. Hypertension Prevention Trial Research Group. J Am Diet Assoc. 1990 Jan;90(1):69-76.
    Results Reference
    background
    PubMed Identifier
    2063702
    Citation
    Schmid TL, Jeffery RW, Onstad L, Corrigan SA. Demographic, knowledge, physiological, and behavioral variables as predictors of compliance with dietary treatment goals in hypertension. Addict Behav. 1991;16(3-4):151-60. doi: 10.1016/0306-4603(91)90007-5.
    Results Reference
    background
    PubMed Identifier
    1877599
    Citation
    Canner PL, Borhani NO, Oberman A, Cutler J, Prineas RJ, Langford H, Hooper FJ. The Hypertension Prevention Trial: assessment of the quality of blood pressure measurements. Am J Epidemiol. 1991 Aug 15;134(4):379-92. doi: 10.1093/oxfordjournals.aje.a116100.
    Results Reference
    background

    Learn more about this trial

    Hypertension Prevention Trial (HPT) Feasibility Study

    We'll reach out to this number within 24 hrs